DUBLIN – Shares in Affimed NV (NASDAQ:AFMD) surged 150 percent during premarket trading Tuesday on news of an alliance with Genentech to develop bispecific drugs that will direct a natural killer (NK) cell response against multiple solid and hematological tumors. Heidelberg, Germany-based Affimed is getting $96 million in up-front and guaranteed near-term funding and could earn as much as $5 billion from development, regulatory and commercial milestones.